Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell Limited has issued 1,367,852 new shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move is part of Orthocell’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its stakeholders by increasing liquidity and financial flexibility.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, nerve reconstruction products, and autologous cell therapies for tendon and cartilage regeneration. Their products are distributed globally, with recent expansions into the US market.
Average Trading Volume: 1,414,370
Technical Sentiment Signal: Buy
Current Market Cap: A$308.5M
Learn more about OCC stock on TipRanks’ Stock Analysis page.